Exact Mass: 1203.8205904000001
Exact Mass Matches: 1203.8205904000001
Found 13 metabolites which its exact mass value is equals to given mass value 1203.8205904000001,
within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error
0.0002 dalton.
Leucinostatin B
C61H109N11O13 (1203.8205904000001)
D000890 - Anti-Infective Agents > D023181 - Antimicrobial Cationic Peptides
Leucinostatin B M+H reference compound
C61H109N11O13 (1203.8205904000001)
(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-9-(2-hydroxy-2-methylpropyl)-6,18,24-triisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,28-octamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
C61H109N11O13 (1203.8205904000001)
(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-33-[(1R,2R,4E)-1,6-dihydroxy-2-methylhex-4-en-1-yl]-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,28-octamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
C61H109N11O13 (1203.8205904000001)
cyclosporin A metabolite M13
C61H109N11O13 (1203.8205904000001)
A cyclosporin A derivative that is cyclosporin A in which the residue-9 N-methylleucine moiety has undergone oxidation so as to introduce a hydroxy group at the carbon bearing the two methyl groups, while the residue-4 N-methylleucine moiety has undergone N-demethylation.
cyclosporin A metabolite M25
C61H109N11O13 (1203.8205904000001)
A cyclosporin A derivative that is cyclosporin A in which residue 1 [(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid] has undergone allylic oxidation to give the corresponding primary allylic alcohol, while residue 4, N-methylleucine, has undergone N-demethylation.
6-hydroxy-2-{[hydroxy({4-methyl-1-[(2e)-4-methylhex-2-enoyl]pyrrolidin-2-yl})methylidene]amino}-n-(2-hydroxy-3-methyl-1-{[1-methyl-1-({3-methyl-1-[(3-methyl-1-{[1-methyl-1-({1-methyl-1-[(2-{[1-(methylamino)propan-2-yl]-c-hydroxycarbonimidoyl}ethyl)-c-hydroxycarbonimidoyl]ethyl}-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}butyl)-c-hydroxycarbonimidoyl]butyl}-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}butyl)-4-methyl-8-oxodecanimidic acid
C61H109N11O13 (1203.8205904000001)
(2r,4r,6s)-6-hydroxy-n-[(1s,2s)-2-hydroxy-3-methyl-1-[(1-methyl-1-{[(1s)-3-methyl-1-{[(1s)-3-methyl-1-{[1-methyl-1-({1-methyl-1-[(2-{[(2s)-1-(methylamino)propan-2-yl]-c-hydroxycarbonimidoyl}ethyl)-c-hydroxycarbonimidoyl]ethyl}-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}butyl]-c-hydroxycarbonimidoyl}butyl]-c-hydroxycarbonimidoyl}ethyl)-c-hydroxycarbonimidoyl]butyl]-2-({hydroxy[(2s,4r)-4-methyl-1-[(2z,4r)-4-methylhex-2-enoyl]pyrrolidin-2-yl]methylidene}amino)-4-methyl-8-oxodecanimidic acid
C61H109N11O13 (1203.8205904000001)
8,14,23,26,32-pentahydroxy-9-(1-hydroxy-2-methylhex-4-en-1-yl)-6-(1-hydroxyethyl)-12,30-diisopropyl-1,4,10,16,19,21,24,28-octamethyl-15,18,27,33-tetrakis(2-methylpropyl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriaconta-7,13,22,25,31-pentaene-2,5,11,17,20,29-hexone
C61H109N11O13 (1203.8205904000001)